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MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES
Noe L1, Neil N1, Ogden K1, Turini M2
1ICON Clinical Research, San Francisco, CA, USA, 2ICON Clinical Research, Milan, Italy
OBJECTIVES: A medical food is formulated to be consumed or administered enterally 
under the supervision of a physician, and is intended for the speciﬁc dietary manage-
ment of a disease or condition for which distinctive nutritional requirements are 
established by medical evaluation. In the US, medical foods are a special product cat-
egory regulated by the FDA. In Europe, a similar category called “Foods for Special 
Medical Purposes” (FSMPs) is covered by the Foods for Particular Nutritional Uses 
directive and regulated by the European Commission (EC). Our objective is to review 
and compare the characteristics of, and regulatory environments for, medical foods 
and FSMPs. METHODS: We conducted internet and PubMed searches to identify 
information and guidance covering medical foods and FSMPs, including relevant FDA 
and EC regulations. We also reviewed and compared the characteristics, place in 
therapy, and potential economic impact of these products. RESULTS: Medical foods 
do not require pre-approval from the FDA for marketing. Unlike nutritional supple-
ments, which have no disease claim and are intended for healthy individuals, medical 
foods must make a disease claim and are intended for use in speciﬁc diseased popula-
tions. Disease claims must be supported by sound scientiﬁc evidence substantiating 
claims of successful nutritional management of the disease. All ingredients must be 
approved food additives or classiﬁed as Generally Recognized as Safe (GRAS). Reim-
bursement for medical foods is inconsistent, and varies by product and by health plan. 
Like medical foods in the US, FSMPs are intended for use only under medical supervi-
sion, but they must comply with EC regulations. There has been little to no economic 
research conducted with products in these categories. CONCLUSIONS: Medical foods 
and FSMPs can play a key role in the nutritional and metabolic support of patients 
with certain diseases and conditions, although their economic impact has not been 
studied.
PHP96
ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN®) IN TOTAL 
PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN 
PATIENTS: A PHARMACOECONOMIC SIMULATION MODEL
Eandi M1, Pradelli L2, Iannazzo S2
1Università di Torino, Torino, Italy, 2AdRes HE&OR, Torino, Italy
OBJECTIVES: Several clinical trials have demonstrated that the supplementation of 
Dipeptiven® in critically ill patients in Intensive Care Units (ICUs) is associated with 
better clinical outcomes, such as reduction of the infection rate, shortening of ICU           
and hospital lengths of stay (LOS), and a trend toward reduced mortality, when 
compared to standard TPN regimens. Aim of the study is the pharmacoeconomic 
evaluation of Dipeptiven vs. standard TPN in critically ill patients admitted to Italian 
ICUs. METHODS: The analysis is based on a Discrete Event Simulation model that 
incorporates: a) baseline outcomes rates from the 2007 GIVITI report (data from 200 
Italian ICUs and over 60,000 patients); b) Dipeptiven® efﬁcacy from systematic review 
and meta-analysis with a Bayesian Random-Effects model of the published clinical 
trials; c) national cost data in the perspective of the hospital from published sources. 
The simulated clinical outcomes are: death rate in ICU; infection rate in ICU; death         
rate in general ward; hospital LOS, divided into LOS pre-ICU, LOS in ICU, and LOS 
in ward (post-ICU). One-way and probabilistic sensitivity analyses were performed 
and the cost/effectiveness acceptability curve generated. RESULTS: Dipeptiven® 
results more effective and less costly than standard TPN reducing mortality rate 
(23.55% o 15.2% vs. 34.50% o 2.06%), infection rate (15.91% o 3.95% vs. 18.97% 
o 3.94%), overall hospital LOS (25.47 o 0.26 vs. 26.00   o 0.27 days) and total cost 
per patient (23,922 o 3,249 vs. 24,145   o a3,361). This indicates that treatment cost 
is completely offset by the reduction in ICU costs, and by antibiotic costs for the 
treatment of ICU-emergent infections. The cost/effectiveness acceptability curve shows      
that Dipepetiven® has an estimated 78% probability of resulting dominant and a 90% 
probability of resulting cost/effective if the decision maker is willing to pay up to 
a1500 to avoid one patient death.  CONCLUSIONS: Dipeptiven® is expected to 
averagely dominate standard TPN, as it results associated with better clinical and 
economic outcomes.
PHP97
THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES 
USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE
Zalis’ka O1, Maynych J2
1Danylo Halytsky Lviv national medical university, Lviv, Ukraine, 2Lviv National Medical 
University named Danylo Galitsky, Lviv, Ukraine
OBJECTIVES: In Ukraine the medical products made in pharmacies by extempore 
use wide demand, is especial for treatment of children though the quantity of the 
pharmacies engaged in extemporal preparation every year decreases in connection 
with economic conditions, features of licensing of such activity in Ukraine. Use extem-
poral preparations with precisely picked up concentration corresponding by the 
medicinal form (the suppositories, a dosed out powder) allows to provide individual-
ized therapy of the child depending on age and weights of the body, accompanying 
diseases (for example a diabetes). METHODS: We have carried out the ÀÂÑ- analysis  
of extemporal medicines, which were prepared in pharmacies of Lviv city for 2008. 
RESULTS: Sample list of extemporal medicines has made 44 names for 2000 recipes. 
The dominating medicinal form solutions with precisely set concentration or features 
of their technological manufacturing make 45%. Also prepare for ointments (21%), 
dosed out powders (18%), suspensions (7%), mixtures (5%), suppositories (4%). 
Among medicinal forms are submitted a solution of clorhydrogenic acid with pepsi-
num, used for excitation of appetite at children, the recipe—Lassar paste for treatment 
of dermatitis at children. Such medicines are not made with a farmaceutical industry. 
CONCLUSIONS: We have deﬁned, that costs of extemporal medicines, in particular 
solutions makes 4–16 UAH (1 $  7.7 UAH), ointments 8–27 UAH, powders of 2–6 
UAN, suspension of 11–18 UAH. These extemporal medicines are economically 
 accessible to treatment for children in Ukraine.
PHP98
COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD 
PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS
Stokes ME1, Shah M2, Williams K3, Reynolds MW3, Rupnow MF4, Hammond J4
1United BioSource Corporation, Dorval, QC, Canada, 2Xcenda, Palm Harbor, FL, USA, 
3United BioSource Corporation, Lexington, MA, USA, 4Ethicon, Inc, Somerville, NJ, USA
OBJECTIVES: Inadequate surgical hemostasis may lead to bleeding related complica-
tions and transfusion. The aim of this analysis was to examine the incidence and costs 
of bleeding complications and blood product transfusions for patients undergoing 
inpatient surgeries. METHODS: A retrospective analysis was conducted using Pre-
mier’s Perspective hospital database. Patients who had a procedure within a specialty 
of interest (i.e. cardiac, vascular, non-cardiac thoracic, solid organ, general, reproduc-
tive organ or knee/hip replacement) in 2006 or 2007 were identiﬁed via ICD-9 pro-
cedure codes. For each specialty, rate of bleeding complications (including bleeding 
event, re-operation to control for bleeding and blood product transfusions) were 
examined, and cost of hospitalizations and length of stay (LOS) were compared 
between surgeries with versus without complications. The incremental costs were 
based on a multivariate analysis adjusting for demographics (e.g., age, gender, geo-
graphic region), hospital characteristics (e.g., urban versus rural, bed size) and other 
baseline characteristics (e.g., comorbidities, admitting diagnosis, prior hospitaliza-
tion). RESULTS: A total of 647,918 cardiac, 725,624 vascular, 227,273 non-cardiac 
thoracic, 139,781 solid organ, 1,586,557 general, 1,032,762 reproductive organ and 
247,682 knee/hip replacement surgeries were identiﬁed. The rate of bleeding complica-
tion was highest for knee/hip replacement (29.8%), followed by vascular (27.1%), 
non-cardiac thoracic (26.5%), solid organ (23%), cardiac (11.7%), general (11.4%) 
and reproductive organ (3.3%). Incremental LOS associated with bleeding complica-
tions or transfusions was 11.5 days for non-cardiac thoracic, 10.5 days for solid organ, 
10.2 days for vascular, 9.6 days for general and 1.3 days for knee/hip replacement 
surgeries. The incremental cost per case of hospitalization associated with complica-
tion was highest for non-cardiac thoracic surgeries ($27,069), followed by vascular 
($26,272), cardiac ($20,261), solid organ ($18,420), general ($7,036), reproductive 
organ ($6,222) and knee/hip replacement ($3,246). CONCLUSIONS: This study 
characterizes the increased hospital LOS and cost associated with bleeding com-
plications and transfusions, and supports implementation of blood conservation 
strategies.
PHP99
A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS  
OF ACUPUNCTURE
Kim SY, Lee H, Park HJ
Kyung Hee University, Seoul, South Korea
OBJECTIVES: Acupuncture is widely used for various diseases such as chronic low 
pain and osteoarthritis, but the cost-effectiveness of acupuncture has not been fully 
explored. The aim of this review is to summarize and assess randomized controlled 
trials (RCTs) of acupuncture for economic evaluation. METHODS: Total 5 electronic 
databases were searched up to May 2009 without language restrictions. The search 
terms used were “cost effectiveness”, “cost utility” and “cost beneﬁt” with “acupunc-
ture”. Studies presenting results of economic evaluation throughout prospective, 
 controlled studies for any medical condition were included. The quality of study was 
assessed. The main outcomes for health beneﬁt and cost were extracted and described. 
RESULTS: Thirteen RCTs that met the inclusion and exclusion criteria underwent a 
full-text review. Acupuncture with usual care was compared with usual care only in 
all studies. Nine studies were applied for pain condition including low back pain, 
headache, and dysmenorrhea. The reporting quality of the studies was poor for certain 
items. Nine studies described incremental cost-effectiveness ratio (ICER) or incremen-
tal cost per quality adjusted life year. Most studies suggested that additional acupunc-
ture treatment was cost-effective compare to the usual care for low back pain, 
headache, dysmenorrhea, osteoarthritis, angina pectoris, and allergic rhinitis. CON-
CLUSIONS: This systematic review showed the cost-effectiveness of additional acu-
puncture treatment, but including studies were very few and applied diseases were 
limited. Therefore the results could not be generalized due to diversity of disease and 
different status of each country. The more number of economic evaluations of 
 acupuncture are necessary to ﬁrm the evidence.
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PHARMACY STUDY OF NATURAL HEALTH PRODUCT ADVERSE 
REACTIONS (SONAR): ACTIVE SURVEILLANCE INCREASES AR 
REPORTING AND REVEALS TWO NEW INTERACTIONS
Cvijovic K1, Boon H1, Jaeger W2, Vohra S3
1University of Toronto, Toronto, ON, Canada, 2University of Vienna, Vienna, Vienna, Austria, 
3University of Alberta, Edmonton, AB, Canada
OBJECTIVES: To implement, and assess the feasibility of an active surveillance model 
in community pharmacies to systematically detect adverse events (AEs) associated with 
the use of natural health products (NHPs) and NHP-drug interactions. METHODS: 
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Pharmacists were instructed to ask each person dropping off or picking up a prescrip-
tion about concurrent NHP-drug use, and the occurrence of any potential AE. Tele-
phone interviews conducted by a study team member were used to follow up if an AE 
was reported. Up to three months of active surveillance was planned in ten community 
pharmacies in Ontario. All cases were independently adjudicated for causality, serious-
ness and outcome by 2 study team members with expertise in NHPs. Algorithms used 
for adjudication included the WHO guidelines, Naranjo causality scale, and Horn 
algorithm (drug interaction probability scale). RESULTS: Over 2000 patients have 
been screened. A total of 759 reported taking NHPs and drugs concurrently, 35 were 
identiﬁed as having suspected AEs, and 15 consented to, and were available for, an 
in-depth interview. Two not previously described probable NHP-drug interactions 
have been identiﬁed including analysis of their purported CYP450 pharmacokinetic 
mechanisms. In case 1, strong sedation occurred after concomitant intake of citalo-
pram, nortriptyline, oxycodone, and melatonin. Melatonin was shown to inhibit 
CYP2C19 and thus citalopram metabolism. In case 2, heart palpitations occurred after 
concomitant intake of two NHPs containing a variety of active substances and pro-
gesterone cream use. Laboratory analyses to investigate possible mechanisms to 
explain the clinical symptoms described is ongoing. CONCLUSIONS: In this study, 
the rate of AEs suspected to be related to NHP use was 5.7%. Active surveillance of 
NHP-drug interactions and NHP-related AEs in community pharmacies is feasible and 
provides an effective way to discover unknown pharmacokinetic and pharmacody-
namic NHP-related interactions.
CANCER – Clinical Outcomes Studies
PCN1
BURDEN OF THROMBOCYTOPENIA IN CANCER PATIENTS 
UNDERGOING CHEMOTHERAPY, 2000–2007
Nalysnyk L1, Wu Y2, Aravind S3, Ranganathan G1
1United BioSource Corporation, Lexington, MA, USA, 2Johnson & Johnson Pharmaceutical 
Services, LLC, Malvern, PA, USA, 3Johnson & Johnson Pharmaceutical Services, LLC, New 
Brunswick, MA, USA
OBJECTIVES: Along with neutropenia and anemia, thrombocytopenia is one of the 
most common hematological complications of cancer treatment. Prolonged/severe 
thrombocytopenia increases the risk of bleeding. The goal of this study was to evalu-
ate the epidemiology of thrombocytopenia among cancer patients on chemotherapy. 
METHODS: Data were collected between 2000–2007 from a large electronic 
medical records database in 18 outpatient oncology clinics throughout the US. Adult 
patients with NSCLC, breast, ovarian, H&N, and colorectal cancers were of inter-
est. Chemotherapy regimens were grouped into platinum-, anthracycline-, gem-
citabine-, and taxane- based. Thrombocytopenia (150,000 Ml) prevalence was 
examined by tumor and regimen type. RESULTS: A total of 47,159 patients [mean 
age 61, male 42%] and 75,243 chemotherapy regimens were analyzed. Breast cancer 
patients constituted 19.5%, followed by NSCLC (14.9%), colorectal (11.9%), 
ovarian (3.1%), and H&N (2.5%). Platinum-based regimens accounted for 27.8% 
of all regimens. Prevalence of post-chemo thrombocytopenia was highest among 
gemcitabine treated patients (64.2%), followed by platinum (55.5%), and lowest 
with taxane-based regimens (21.9%). Most of the patients across all treatment 
regimen groups presented with thrombocytopenia (grade 1). Eleven percent of 
patients on platinum and gemcitabine regimens, 2% in taxane-treated patients, and 
5% in anthracycline-treated patients had PC  50 r 109/L (grade 3–4). Patients with 
NSCLC and ovarian cancer had the highest incidence of thrombocytopenia. A sub-
stantial proportion of patients, 30% developed both anemia and thrombocytopenia 
after chemotherapy start. More than 90% of patients with thrombocytopenia grade 
1–3 also had anemia grade 1 or 2. Twenty percent of those with grade 4 thrombocy-
topenia presented with anemia grade 3–4. Of these, 16.7% had NSCLC, 16.2% 
were breast cancer patients, and 9.1% were colorectal cancer patients. Platelet trans-
fusions were rare (5% of all chemotherapy-treated patients). CONCLUSIONS: 
Thrombocytopenia was common in this large cohort of cancer patients on 
 chemotherapy. A substantial proportion of patients developed both anemia and 
thrombocytopenia.
PCN2
DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING 
CHEMOTHERAPY
Nalysnyk L1, Wu Y2, Aravind S3, Ranganathan G1
1United BioSource Corporation, Lexington, MA, USA, 2Johnson & Johnson Pharmaceutical 
Services, LLC, Malvern, PA, USA, 3Johnson & Johnson Pharmaceutical Services, LLC, New 
Brunswick, MA, USA
OBJECTIVES: Cancer patients receiving chemotherapy may often require chemo-
therapy dose delays and dose reductions due to chemotherapy-induced side effects 
such as thrombocytopenia, neutropenia, and anemia. In responsive cancers, such dose 
delay and dose reduction of chemotherapy may be associated with decreased effective-
ness and poorer clinical outcomes. In this study, we analyzed the characteristics of 
dose delay among cancer patients on chemotherapy. METHODS: Data from 2000–
2007 from a large electronic database of outpatient oncology clinics in the US were 
analyzed. Adult patients with a cancer diagnosis and complete chemotherapy plan 
information were eligible for this analysis. Chemotherapies were grouped into plati-
num-, anthracycline-, gemcitabine-, taxane-based, and other. The planned cycle dura-
tion was compared to the actual duration. A difference of more than 7 days was 
deﬁned as a cycle delay. RESULTS: The dataset included 47,159 cancer patients (mean 
age 61 (SD 13), male 42%) and 75,243 chemotherapy regimens. A total of 26,317 
patients (113,175 chemo cycles) had complete chemotherapy plan information. Of 
these, 5961 (22.7%) experienced chemo delays in 9293 cycles (8%) during chemo-
therapy. The average length of delay was 17 days (SD, 8 days; median, 14 days); 25% 
of the delays were more than 3 weeks. Tumor types of the 5,961 patients with cycle 
delays included, colorectal cancer (20.3%), NSCLC (18.6%), breast cancer (15.2%), 
ovarian (4.4%), and H&N (2.9%). The reasons for delaying chemo were not speciﬁed 
in the database. However, many (60%) experienced anemia (Hb  11 g/dL) or throm-
bocytopenia (150,000 Ml, 62%) at some point during chemotherapy. CONCLU-
SIONS: Chemotherapy cycle delays were relatively common in this large group of 
cancer patients. While decisions to delay therapy were multi-factorial, further research 
is needed to investigate the reasons, preventable measures, clinical and cost outcomes 
of these delays.
PCN3
HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF 
COMORBIDITY COMPARED TO CANCER-FREE CONTROLS
van Herk-Sukel MPP1, Landis SH2, van den Haak P1, Janssen-Heijnen ML3, El-Hariry IA2, 
Penning-van Beest FJA1, Herings RM1
1PHARMO Institute, Utrecht, Utrecht, The Netherlands, 2GlaxoSmithKline, Greenford, UK, 
3Eindhoven Cancer Registry, Eindhoven, The Netherlands
OBJECTIVES: As comorbidity has a direct impact on choice of cancer treatment and 
patient prognosis after diagnosis, this study compared the prevalence and incidence 
of comorbidity among head and neck cancer (HNC) patients to a cancer-free popula-
tion in the Netherlands. METHODS: Patients diagnosed with oral cavity, pharynx 
(excluding nasopharynx), and larynx cancer between 2000–2006 were selected from 
the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient was matched 
by age and gender to four cancer-free controls selected from the PHARMO RLS with 
date of cancer diagnosis selected as the index date for both cohorts. Comorbidities 
including diabetes, cardiovascular disease (CVD), anaemia, asthma/COPD, pneumo-
nia, and depression were identiﬁed by prescription and/or hospitalisation data. Preva-
lence ratios and hazard ratios (HRs) were used to compare the occurence of events 
before and after diagnosis, respectively. RESULTS: Patients diagnosed with oral 
cavity, pharynx (excluding nasopharynx), and larynx cancer between 2000–2006 were 
selected from the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient 
was matched by age and gender to four cancer-free controls selected from the 
PHARMO RLS with date of cancer diagnosis selected as the index date for both 
cohorts. Comorbidities including diabetes, cardiovascular disease (CVD), anaemia, 
asthma/COPD, pneumonia, and depression were identiﬁed by prescription and/or 
hospitalisation data. Prevalence ratios and hazard ratios (HRs) were used to compare 
the occurence of events before and after diagnosis, respectively. CONCLUSIONS: 
HNC patients suffer from signiﬁcantly higher prevalence and incidence of both chronic 
and acute comorbidies, compared to cancer-free controls. These conditions may affect 
patient eligibity for aggressive treatment and place them at higher mortality risk.
PCN4
BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT. 
A SYSTEMATIC REVIEW
Palaska PK1, Cartsos V2, Zavras A1
1Harvard University, Boston, MA, USA, 2Tufts University, Boston, MA, USA
OBJECTIVES: Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a com-
plication of long-term bisphosphonate (BP) use. Given the beneﬁcial effects of BP on 
bone quality in patients with cancer or osteoporosis, it is of great importance to review 
the risk as it relates to time-to-event or the cumulative dose until the onset of the 
disease. METHODS: Here, we report on a review of 71 case series published since 
2003. We calculated the weighted means of time to event, as well as the minimum 
reported time and dose for zoledronate, pamidronate, and oral bisphosphonates. 
RESULTS: The mean time to BONJ after zoledronate treatment was calculated at 1.8 
years and the minimum was 10 months; after pamidronate the mean time was 2.8 
years and the minimum was 18 months; and after oral BP therapy the mean time was 
4.6 years and the minimum was 3 years. CONCLUSIONS: Zoledronic acid seems to 
be the most potent among the N-containing BPs. Factors that seem to affect BONJ 
and time to event were invasive dental procedures, and other comorbid factors such 
as increased age, rheumatoid arthritis, diabetes, use of corticosteroids, Vitamin D 
deﬁciency, and more. Understanding the pathophysiology of the disease requires 
further research.
PCN5
RENAL CELL CARCINOMA PATIENTS ARE TWICE AS LIKELY TO 
DEVELOP THROMBOEMBOLIC EVENTS COMPARED TO  
CANCER-FREE CONTROLS
van Herk-Sukel MPP1, Shantakumar S2, Casparie MK3, Abrahamson PE4,  
Penning-van Beest FJA1, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 
2GlaxoSmithKline, Research Triangle Park, NC, USA, 3PALGA, Utrecht, The Netherlands, 
4Salmon Bay Epidemiology, Seattle, WA, USA
OBJECTIVES: To study occurrence of thromboembolic (TE) events before and after 
RCC diagnosis compared to cancer-free controls as this information is lacking in 
published literature. METHODS: RCC patients were selected from PALGA, a Dutch 
pathology database, and linked to the PHARMO record linkage system (PHARMO 
RLS) which includes drug use and hospitalization data in the Netherlands. RCC 
